In some cases, the possible growth of residual tumors and remote micrometastases may also initiate angiogenesis by releasing Ang2.[18] The long duration of high level plasma Ang2 caused by surgery may justify the administration of anti-Ang2 therapy for NSCLC in the postoperative adjuvant setting. Here, ANGPT2 is linked to non-small cell lung carcinoma.